cagrilintide novo Nordisk flags promise in hunt for next obesity drug Novo Nordisk's CagriSema: First Fixed-Dose
Novo Nordisk's CagriSema: First Fixed Dose GLP 1 + Amylin Combination Mohd Umar posted on the topic LinkedIn Novo Nordisk announces positive results for CagriSema in type 2 diabetes PMLiVE Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement # Weight loss: New drug CagriSema leads to 14% weight loss in trial
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9

